



RIGHT DRUG. RIGHT PATIENT. RIGHT TIME.

3TR looks at seven different immune-mediated diseases both in parallel and jointly to fundamentally increase our understanding of the molecular patterns behind these diseases. This will help enhance patient and disease management, and pave the way for new treatment approaches in the future.

INTEGRATED, CROSS-DISEASE ANALYSIS OF SEVEN DISEASES

**CHRONIC OBSTRUCTIVE
PULMONARY DISEASE**

ASTHMA

CROHN'S DISEASE

ULCERATIVE COLITIS

7

MULTIPLE SCLEROSIS

**SYSTEMIC LUPUS
ERYTHEMATOSUS**

RHEUMATOID ARTHRITIS

www.3tr-imi.eu

3TR is the largest immunology project funded by the Innovative Medicine Initiative (IMI) to date.

With access to an unprecedented quantity of clinical data and samples of more than 50,000 patients across 50 clinical trials, the team will provide fundamental new insights into the mechanisms of non-response to treatment.

KEY OBJECTIVES

- Perform comprehensive molecular and clinical characterisation of a prospective patient cohort
- Establish a centralised data and sample management platform
- Deliver integrated analyses of all data using advanced bioinformatics/statistical and modelling methods
- Identify sets of predictive biomarkers of response/non-response to therapies
- Promote a scientific evidence-based rationale for treatment selection to enhance disease management



80 MILLION



84 MONTHS



15 COUNTRIES



69 PARTNERS

 **@3TR_IMI**

www.3tr-imi.eu



Innovative
medicines
initiative



efpia

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 831434. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.